Cellectis (NASDAQ:CLLS) Lowered to Hold Rating by StockNews.com

StockNews.com lowered shares of Cellectis (NASDAQ:CLLS) from a buy rating to a hold rating in a report published on Thursday morning.

Cellectis Price Performance

Cellectis stock opened at $1.45 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. The stock has a market cap of $80.60 million, a price-to-earnings ratio of -1.12 and a beta of 3.22. The firm has a 50-day moving average of $1.34 and a two-hundred day moving average of $1.64. Cellectis has a 1 year low of $1.10 and a 1 year high of $3.38.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.22). The firm had revenue of $33.22 million during the quarter, compared to analysts’ expectations of $5.90 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. On average, research analysts forecast that Cellectis will post -0.46 earnings per share for the current year.

Institutional Trading of Cellectis

Several institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN grew its holdings in Cellectis by 103.4% during the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 12,500 shares in the last quarter. B Group Inc. purchased a new stake in shares of Cellectis in the 4th quarter worth approximately $5,547,000. Finally, Millennium Management LLC bought a new position in shares of Cellectis during the fourth quarter valued at approximately $962,000. 63.90% of the stock is currently owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.